Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

China’s SIMM, French Drugmaker Servier To Collaborate On Anti-Tumor Medicine R&D

This article was originally published in PharmAsia News

Executive Summary

Shanghai Institute of Materia Medica (SIMM) and French pharmaceutical company Servier Laboratories signed an agreement on the R&D of targeted antitumor drug candidate lucitanib.

You may also be interested in...



Finance Watch: 5AM, Longevity Close Funds, New Incubators Launch To Support Early-Stage Companies

News of 5AM's two latest venture funds follows the launch of Longevity Vision Fund as well as LA BioMed's and RUNLABS’ announcements that they will open new incubators in 2019. Also, Passage Bio launches with $115.5m, but the largest recent VC deal was HaiHe's $146.6m financing.

Travere Looks Ahead To Phase III In Homocystinuria

The latest data from a Phase I/II study shows that pegtibatinase can yield a rapid, sustained reduction in homocysteine, the protein behind the underlying cause of the rare disease.

Minute Insight: Inbound Health Now Offers Post-Surgical Hospital Care At Patients’ Homes

The hospital-to-home care movement is rising, and Inbound Health wants to be at the forefront of enabling health systems and health plans nationwide to bring hospital-level care into the home, now adding general surgery to its offerings.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

SC085578

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel